Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis
Open Access
- 5 August 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 52 (5), 1713-1722
- https://doi.org/10.1002/hep.23892
Abstract
Obesity is rapidly becoming a pandemic and is associated with increased carcinogenesis. Obese populations have higher circulating levels of leptin in contrast to low concentrations of adiponectin. Hence, it is important to evaluate the dynamic role between adiponectin and leptin in obesity‐related carcinogenesis. Recently, we reported the oncogenic role of leptin including its potential to increase tumor invasiveness and migration of hepatocellular carcinoma (HCC) cells. In the present study we investigated whether adiponectin could antagonize the oncogenic actions of leptin in HCC. We employed HCC cell lines HepG2 and Huh7, the nude mice‐xenograft model of HCC, and immunohistochemistry data from tissue‐microarray to demonstrate the antagonistic role of adiponectin on the oncogenic actions of leptin. Adiponectin treatment inhibited leptin‐induced cell proliferation of HCC cells. Using scratch‐migration and electric cell‐substrate impedance‐sensing‐based migration assays, we found that adiponectin inhibited leptin‐induced migration of HCC cells. Adiponectin treatment effectively blocked leptin‐induced invasion of HCC cells in Matrigel invasion assays. Although leptin inhibited apoptosis in HCC cells, we found that adiponectin treatment induced apoptosis even in the presence of leptin. Analysis of the underlying molecular mechanisms revealed that adiponectin treatment reduced leptin‐induced Stat3 and Akt phosphorylation. Adiponectin also increased suppressor of cytokine signaling (SOCS3), a physiologic negative regulator of leptin signal transduction. Importantly, adiponectin significantly reduced leptin‐induced tumor burden in nude mice. In HCC samples, leptin expression significantly correlated with HCC proliferation as evaluated by Ki‐67, whereas adiponectin expression correlated significantly with increased disease‐free survival and inversely with tumor size and local recurrence. Conclusion: Collectively, these data demonstrate that adiponectin has the molecular potential to inhibit the oncogenic actions of leptin by blocking downstream effector molecules. (HEPATOLOGY 2010This publication has 41 references indexed in Scilit:
- Leptin-induced Growth Stimulation of Breast Cancer Cells Involves Recruitment of Histone Acetyltransferases and Mediator Complex to CYCLIN D1 Promoter via Activation of Stat3Published by Elsevier BV ,2007
- Adiponectin and Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- The clinical uses of leptinCurrent Opinion in Pharmacology, 2003
- Association of serum adiponectin levels with breast cancer risk.2003
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003
- Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. AdultsThe New England Journal of Medicine, 2003
- Adiponectin and protection against type 2 diabetes mellitusThe Lancet, 2003
- Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from AtherosclerosisPublished by Elsevier BV ,2003
- Peripheral metabolic actions of leptinBest Practice & Research Clinical Endocrinology & Metabolism, 2002
- The adipocyte-secreted protein Acrp30 enhances hepatic insulin actionNature Medicine, 2001